Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / COM NEW
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
3,888,235
-
Shares change
-
+13,867
-
Total reported value, excl. options
-
$8,295,086
-
Value change
-
-$6,442
-
Put/Call ratio
-
1.32%
-
Number of buys
-
12
-
Number of sells
-
-15
-
Price
-
$2.13
Significant Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q3 2017
58 filings reported holding GALT - GALECTIN THERAPEUTICS INC - COM NEW as of Q3 2017.
GALECTIN THERAPEUTICS INC - COM NEW (GALT) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3,888,235 shares
.
Largest 10 shareholders include VANGUARD GROUP INC (850,948 shares), D.A. DAVIDSON & CO. (690,960 shares), Advisor Group, Inc. (519,850 shares), BlackRock Inc. (200,378 shares), GEODE CAPITAL MANAGEMENT, LLC (195,411 shares), Benchmark Capital Advisors (194,200 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (168,648 shares), COURAGE CAPITAL MANAGEMENT LLC (130,000 shares), US BANCORP \DE\ (118,921 shares), and MORGAN STANLEY (102,736 shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.